Pyrrolidino-tetrahydroisoquinolines bearing pendant heterocycles as potent dual H3 antagonist and serotonin transporter inhibitors
摘要:
A series of novel and potent 6-heteroaryl-pyrrolidino-tetrahydroisoquinolines with dual histamine H-3 antagonist/serotonin transporter inhibitor activity is described. In vitro and in vivo data are discussed. (c) 2007 Elsevier Ltd. All rights reserved.
[EN] SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] IMIDAZOLE CARBOXAMIDES SUBSTITUÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
申请人:BIAL BIOTECH INVEST INC
公开号:WO2021055612A1
公开(公告)日:2021-03-25
The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.
Pyrrolidino-tetrahydroisoquinolines bearing pendant heterocycles as potent dual H3 antagonist and serotonin transporter inhibitors
作者:John M. Keith、Leslie A. Gomez、Ann J. Barbier、Sandy J. Wilson、Jamin D. Boggs、Brian Lord、Curt Mazur、Leah Aluisio、Timothy W. Lovenberg、Nicholas I. Carruthers
DOI:10.1016/j.bmcl.2007.03.043
日期:2007.8
A series of novel and potent 6-heteroaryl-pyrrolidino-tetrahydroisoquinolines with dual histamine H-3 antagonist/serotonin transporter inhibitor activity is described. In vitro and in vivo data are discussed. (c) 2007 Elsevier Ltd. All rights reserved.
Substituted sulfonamides as selective .beta.-3 agonists for the
申请人:Merck & Co., Inc.
公开号:US05705515A1
公开(公告)日:1998-01-06
Substituted sulfonamides are selective .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.